Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor.
Enz
A
A
Preclinical Research CNS Department, Sandoz Pharma Ltd., Basle, Switzerland.
Boddeke
H
H
Gray
J
J
Spiegel
R
R
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D002219:Carbamates / Q000378:metabolism / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D048448:Phenylcarbamates; D010830:Physostigmine / Q000378:metabolism / Q000627:therapeutic use; D010919:Placebos; D051381:Rats; D000068836:Rivastigmine
D002219:Carbamates; D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D010919:Placebos; D010830:Physostigmine; D000068836:Rivastigmine